DK0752885T3 - Terapeutisk inhibitor for celler i den glatte karmuskulatur - Google Patents

Terapeutisk inhibitor for celler i den glatte karmuskulatur

Info

Publication number
DK0752885T3
DK0752885T3 DK94911762T DK94911762T DK0752885T3 DK 0752885 T3 DK0752885 T3 DK 0752885T3 DK 94911762 T DK94911762 T DK 94911762T DK 94911762 T DK94911762 T DK 94911762T DK 0752885 T3 DK0752885 T3 DK 0752885T3
Authority
DK
Denmark
Prior art keywords
muscle cells
therapeutic inhibitor
vascular muscle
smooth vascular
smooth
Prior art date
Application number
DK94911762T
Other languages
Danish (da)
English (en)
Inventor
Lawrence L Kunz
Original Assignee
Neorx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp filed Critical Neorx Corp
Application granted granted Critical
Publication of DK0752885T3 publication Critical patent/DK0752885T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ceramic Engineering (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94911762T 1992-09-25 1992-09-25 Terapeutisk inhibitor for celler i den glatte karmuskulatur DK0752885T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1992/008220 WO1994007529A1 (en) 1992-09-25 1992-09-25 Therapeutic inhibitor of vascular smooth muscle cells
CA002145093A CA2145093C (en) 1992-09-25 1992-09-25 Therapeutic inhibitor of vascular smooth muscle cells

Publications (1)

Publication Number Publication Date
DK0752885T3 true DK0752885T3 (da) 2003-11-03

Family

ID=25677850

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94911762T DK0752885T3 (da) 1992-09-25 1992-09-25 Terapeutisk inhibitor for celler i den glatte karmuskulatur

Country Status (4)

Country Link
EP (1) EP0752885B1 (de)
CA (1) CA2145093C (de)
DK (1) DK0752885T3 (de)
WO (1) WO1994007529A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
WO1994016706A1 (en) 1993-01-28 1994-08-04 Neorx Corporation Therapeutic inhibitors of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
NZ268326A (en) 1993-07-19 1997-12-19 Angiogenesis Tech Inc Stent with a coating comprising an anti-angiogenic compound, such as taxol, and a polymeric carrier
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
AU2494199A (en) 1998-02-10 1999-08-23 Angiosonics, Inc. Apparatus and method for inhibiting restenosis by applying ultrasound energy together with drugs
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6927223B1 (en) 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
ATE300255T1 (de) 2000-10-16 2005-08-15 Conor Medsystems Inc Expandierbare medizinische vorrichtung zum zuführen eines heilmittels
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
EP1575481A4 (de) 2002-03-01 2010-01-06 Celltech R & D Inc Verfahren zur erhöhung oder verringerung der knochendichte
WO2004004702A2 (en) 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
WO2004045531A2 (en) 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
ATE481422T1 (de) 2002-11-21 2010-10-15 Celltech R & D Inc Modulieren von immunantworten
US7098189B2 (en) 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
US7164008B2 (en) 2003-11-17 2007-01-16 University Of Iowa Research Foundation Isolated complexes of endotoxin and MD-2
US8613934B2 (en) 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
US7485666B2 (en) 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
WO2006112869A2 (en) 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
ATE479704T1 (de) 2004-08-18 2010-09-15 Novabiotics Ltd Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv
US7413729B2 (en) 2005-01-13 2008-08-19 University Of Iowa Research Foundation Sialic acid permease system
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
ES2986867T3 (es) 2005-03-03 2024-11-12 Mirus Llc Aleaciones metálicas mejoradas para dispositivos médicos
US7868159B2 (en) 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
MX2008008291A (es) 2005-12-22 2008-09-03 Novabiotics Ltd Peptidos antimicrobianos ciclicos.
US8088396B2 (en) 2006-03-01 2012-01-03 University Of Iowa Research Foundation Isolated complexes of endotoxin and modified MD-2
WO2008036838A2 (en) 2006-09-20 2008-03-27 University Of Iowa Research Foundation Isolated complexes of covalently cross-linked endotoxin and modified md-2
WO2008116347A1 (en) 2007-03-26 2008-10-02 General Regeneratives Limited Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
US8258286B2 (en) 2007-04-26 2012-09-04 University Of Iowa Research Foundation Reduction of off-target RNA interference toxicity
CA2903133C (en) 2007-05-31 2021-10-19 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal
JP2011505144A (ja) 2007-11-30 2011-02-24 ベイラー カレッジ オブ メディシン 樹状細胞ワクチン組成物およびその使用
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
AR067447A1 (es) 2008-07-03 2009-10-14 Monte Verde S A Un procedimiento para preparar una composicion farmaceutica que contiene los proincipios activos glucosamina y meloxicam y el uso de dicha asociacion para el tratamiento de patologias degenerativas osteo-articulares
WO2011038002A1 (en) 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
EP2468269A1 (de) 2010-11-26 2012-06-27 Universitätsklinikum Münster Nitridoxidspender bei der Behandlung von Nitridoxidmangel-induzierten Störungen der Hirnmikrozirkulation
WO2012076842A1 (en) 2010-12-09 2012-06-14 University Of Durham Synthetic retinoids for control of cell differentiation
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
WO2012109667A1 (en) 2011-02-12 2012-08-16 University Of Iowa Research Foundation Therapeutic compounds
AU2012321317B2 (en) 2011-07-12 2016-01-28 Inovio Pharmaceuticals, Inc Novel clostridium difficile DNA vaccine
WO2013013178A1 (en) 2011-07-21 2013-01-24 Kansas State University Research Foundation Sesquiterpenes for antifungal applications
WO2014011663A1 (en) 2012-07-09 2014-01-16 Board Of Trustees Of Michigan State University Inhibitors of bacterial diguanylate cyclase
US9512425B2 (en) 2012-10-23 2016-12-06 Cornell University Inhibiting migration of cancer cells
EP2951199A4 (de) 2013-01-31 2016-07-20 Univ Jefferson Fusionsproteine zur modulation von regulatorischen und effektor-t-zellen
US8957044B2 (en) 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
ES2733030T3 (es) 2013-08-09 2019-11-27 Scripps Research Inst Diseño de transcriptoma completo de moléculas pequeñas bioactivas, selectivas que seleccionan como diana ARN
EP3039126B1 (de) 2013-08-26 2019-10-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Kleinmolekülige zelluläre reprogrammierung zur erzeugung neuronaler zellen
EP3043822A1 (de) 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Zusammensetzungen zur herstellung von kardiomyozyten
WO2015179525A1 (en) 2014-05-20 2015-11-26 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
BR112016030273A8 (pt) 2014-06-24 2021-05-18 Icon Medical Corp dispositivo médico e método para formar o referido dispositivo
WO2016040347A2 (en) 2014-09-08 2016-03-17 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof
US9758781B2 (en) 2014-09-30 2017-09-12 University Of Iowa Research Foundation Methods to prevent and treat autosomal dominant non-syndromic hearing loss
EP3261675A1 (de) 2015-02-25 2018-01-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Sialylierungserhöhende therapien für erkrankungen im zusammenhang mit oxidativem stress
US11027024B2 (en) 2015-05-29 2021-06-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
WO2017027280A1 (en) 2015-08-07 2017-02-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Chemical reprogramming to generate neuronal cells
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
WO2018009825A1 (en) 2016-07-08 2018-01-11 The Scripps Research Institute Desensitizing mast cells by co-presentation of antigens with high affinity mast cell siglec ligands
WO2018224813A1 (en) 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
US11154606B2 (en) 2017-07-05 2021-10-26 Arizona Board Of Regents On Behalf Of Arizona State University Vaccine for prevention of necrotic enteritis in poultry
JP7197556B2 (ja) 2017-07-10 2022-12-27 コーネル・ユニバーシティー がん治療のための染色体不安定性および下流サイトゾルｄｎａシグナル伝達をターゲティングする方法
WO2019018666A1 (en) 2017-07-21 2019-01-24 University Of North Dakota INHIBITION OF FAK-AKT INTERACTION TO INHIBIT METASTASES
SG11202102058UA (en) 2018-08-30 2021-03-30 Tenaya Therapeutics Inc Cardiac cell reprogramming with myocardin and ascl1
CA3116637A1 (en) 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
AU2019240609B2 (en) * 2018-10-29 2025-12-11 Consejo Nacional de Investigaciones Científcas Y Técnicas (Conicet) TGF- ß receptor II isoform, fusion peptide, methods of treatment and methods in vitro
US20220089670A1 (en) 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
JP7630176B2 (ja) 2019-04-01 2025-02-17 テナヤ セラピューティクス， インコーポレイテッド 操作されたカプシドを有するアデノ随伴ウイルス
WO2021007515A1 (en) 2019-07-11 2021-01-14 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
US20230037822A1 (en) 2019-10-28 2023-02-09 The Scripps Research Institute Immune cell receptor antibodies conjugated to high affinity siglec-ligands
US20230053688A1 (en) 2020-01-10 2023-02-23 Cornell University Methods to alter latency in ebv+ malignancies
WO2022076648A1 (en) 2020-10-09 2022-04-14 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
JP2024503719A (ja) 2021-01-19 2024-01-26 ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン ヒトｔ細胞の機能を強化するための遺伝子活性化標的
EP4543459A1 (de) 2022-06-23 2025-04-30 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Hmgb1-inhibitoren zur behandlung von apoe4-bedingten tauopathien mit morbus alzheimer
WO2024097418A2 (en) 2022-11-03 2024-05-10 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Gene activation and interference targets for exhaustion/dysfunction-resistant t cell products and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5026537A (en) * 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque
WO1993004191A1 (en) * 1991-08-15 1993-03-04 Neorx Corporation Noncytolytic toxin conjugates

Also Published As

Publication number Publication date
EP0752885B1 (de) 2003-07-09
CA2145093C (en) 2007-04-10
WO1994007529A1 (en) 1994-04-14
EP0752885A4 (de) 1996-02-06
CA2145093A1 (en) 1994-04-14
EP0752885A1 (de) 1997-01-15

Similar Documents

Publication Publication Date Title
DK0752885T3 (da) Terapeutisk inhibitor for celler i den glatte karmuskulatur
FI933202L (fi) Hartsregleringsbehandling
FI970214A7 (fi) Droloksifeenin käyttö sydänverisuonitautien hoitamiseksi
EP0746377A4 (de) Tandem-auftragekompresse für therapeutische wirkstoffe
MX18467A (es) Agentes terapeuticos de quinuclidinas
DE4396657T1 (de) Gefäßprothese
FI943805L (fi) Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon
ITMI922953A1 (it) Inibitori a doppia attivita' biologica di no sintasi e cicloossigenasi procedimento per la loro preparazione e composizioni terapeutiche che li contengono.
FI954541A7 (fi) Keratinosyyttikasvutekijän terapeuttisia käyttöjä
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
FI951306A0 (fi) Otsoniystävällinen sterilointiaineseos
KR950700702A (ko) 심장 카테터(Cardiac catheter)
FI973023L (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
GB2271579B (en) Treatment of wood
IT1271567B (it) Procedimento per l'ulteriore trattamento di salcicce
NO970257L (no) Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer
NO940190L (no) Anvendelse av alpha-ketoglutarat
FI895229A7 (fi) Yhdisteitä virtsan pidätyskyvyttömyyden hoitoon
DE69224388D1 (de) Verbesserung der muskeltätigkeit
GB9120748D0 (en) Inhibition of vascular smooth muscle cell proliferation
NO953480D0 (no) Anvendelse av, og metode ved behandling som anvender, carbazolyl-(4)-oksypropylamin-forbindelser for inhibering av glatt-muskelcelle-formering
EP0722733A4 (de) Hemmer der verdickung von blutgefaessen und der migration von fasern der glatten muskulatur, die beide eine 7-thiaprostaglandin e1-verbindung als aktiven bestandteil enthalten
GB9216360D0 (en) Treatment of blood
ITMI930630A0 (it) Procedimento per la copolimerizzazione dell'etilene
GB2266241B (en) Treatment of pastures